LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024.
Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
Contact:
Olivia Manser
+44 (0) 7780 471568
This email address is being protected from spambots. You need JavaScript enabled to view it.
Julia Wilson
+44 (0) 7818 430877
This email address is being protected from spambots. You need JavaScript enabled to view it.
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.08 |
| Daily Change: | 0.07 2.33 |
| Daily Volume: | 2,708,778 |
| Market Cap: | US$819.560M |
November 12, 2024 October 16, 2024 August 27, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
